AstraZeneca

News

Lynparza set for narrow prostate cancer use after FDA vote

AstraZeneca and partner Merck & Co look set to have a much narrower label for their PARP inhibitor Lynparza in prostate cancer than they were hoping for in the US.

News

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

AstraZeneca have broken out the data they teased last month for transthyretin amyloidosis (ATTR) therapy eplontersen, showing that the drug was effective at slowing down d

News

Inquest says doctor died of COVID-19 jab complication

An inquest in the UK has concluded that the death of a UK doctor in January 2021 shortly after being immunised against COVID-19 was a “rare and unintended complication” of

R&D

What’s next for oncology research?

Eliminating cancer as a cause of death is a highly ambitious goal, but oncology researchers are showing no signs of giving up the fight in 2023.

News

GSK told to pay higher royalties to AZ on Zejula sales

A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ovarian cancer drug Zejula, which competes with AZ’s top-selling PARP inhibito

News

Lynparza gets OK for use in prostate, breast cancers on NHS

AstraZeneca and Merck & Co’s Lynparza will be made available to prostate and breast cancer patients in England and Wales, after cost-effectiveness assessor NICE backed

Lynparza set for narrow prostate cancer use after FDA vote

AZ, Ionis hail phase 3 data for ATTR drug eplontersen

Inquest says doctor died of COVID-19 jab complication

What’s next for oncology research?

GSK told to pay higher royalties to AZ on Zejula sales

Lynparza gets OK for use in prostate, breast cancers on NHS

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

AstraZeneca

Editor's Picks